Related Experiment Videos
Studies on retinotoxic potential of a novel antitumor antibiotic--sparsomycin--in rats
Z Zylicz1, W J De Grip, D J Wagener
1Department of Internal Medicine, St. Radboud University Hospital, Nijmegen, The Netherlands.
Abstract:
Sparsomycin (Sm) is a potent inhibitor of protein synthesis with an anticancer potential. Two years after its discovery in 1962 a phase I clinical trial revealed serious drug-induced retinotoxicity. The mechanism of this toxicity still remains unresolved; however, its understanding is important for the reintroduction of Sm or one of its analogues in clinical practice. If Sm penetrates the retina, its toxic effect should be seen as inhibition of a protein(s) vital for the visual function. Treatment of healthy albino rats and Royal College of Surgeon (RCS) rats with subtoxic doses of Sm was unable to produce ocular toxic effects. Disruption of the blood-retina barrier with sodium iodate allowed Sm to decrease opsin content by only 27%. These results strongly indicate that Sm might become retinotoxic solely upon extreme conditions such as permeabilization of the blood-retina barrier which may happen only in some rare pathological situations.
Insights
Sparsomycin (Sm) shows anticancer potential but caused severe retinotoxicity in trials. Its toxicity appears linked to extreme conditions, like a compromised blood-retina barrier, rather than general use.
Area of Science:
- Biochemistry
- Ophthalmology
- Pharmacology
Background:
- Sparsomycin (Sm) is a protein synthesis inhibitor with anticancer properties.
- A Phase I clinical trial revealed significant drug-induced retinotoxicity, with the mechanism remaining unclear.
- Understanding Sm's retinotoxicity is crucial for potential reintroduction of Sm or its analogues.
Purpose of the Study:
- To investigate the mechanism underlying Sparsomycin-induced retinotoxicity.
- To determine if Sm directly causes ocular toxicity in healthy and genetically compromised animal models.
- To assess the role of the blood-retina barrier integrity in Sm's toxic effects on the retina.
Main Methods:
- Administration of subtoxic doses of Sparsomycin to healthy albino rats and Royal College of Surgeon (RCS) rats.
- Experimental disruption of the blood-retina barrier using sodium iodate.
- Quantification of opsin content as a measure of retinal toxicity.
Main Results:
- Subtoxic doses of Sm did not induce ocular toxic effects in either healthy or RCS rats.
- Disruption of the blood-retina barrier allowed Sm to reduce opsin content by only 27%.
- These findings suggest Sm's retinotoxicity is conditional and requires specific pathological circumstances.
Conclusions:
- Sparsomycin's retinotoxicity is unlikely to occur under normal physiological conditions.
- Retinotoxicity may manifest only when the blood-retina barrier is compromised, a rare pathological event.
- Further research into Sm's interaction with retinal proteins under barrier-compromised conditions is warranted.